SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged violations of federal securities laws, specifically regarding misleading statements about its ELEVIDYS therapy [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false and misleading statements that led investors to believe that the ELEVIDYS therapy was safe and had potential for broader approval [2]. - Allegations include misleading information about the revenue outlook for ELEVIDYS and the therapy's growth potential due to perceived lack of barriers to wider use [2]. Group 2: Investor Participation - Shareholders who purchased Sarepta's securities between June 22, 2023, and June 24, 2025, are encouraged to contact the law firm before August 25, 2025, to participate in the lawsuit [1][3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].